Cingulate Inc. (CING)

NCM – Цена в реальном времени. Валюта: USD

4.96

+0.20 (4.20%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

4.99

+0.03 (0.60%)

После закрытия: Jun 26, 2026, 7:59 PM EDT

16.06.2026

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

04.06.2026

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-term CTx-1301 setup from a PDUFA driven approval event to a CMC-driven resubmission process, while leaving the core product thesis intact based on the information disclosed.

02.06.2026

US FDA declines to approve Cingulate's ADHD drug

Cingulate said on ‌Tuesday that the U.S. Food ⁠and Drug Administration declined to approve its drug to ‌treat ⁠attention deficit hyperactivity disorder.

02.06.2026

Cingulate Receives Complete Response Letter from FDA for CTx-1301

No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter for its New Drug Application (“NDA”) for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).

14.05.2026

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.

06.04.2026

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance.

16.03.2026

Why did Cingulate stock skyrocket today?

Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Tablet.” This regulatory victory effectively safeguards the proprietary technology behind Cingulate's lead ADHD candidate – CTx-1301 – providing a massive boost to investor confidence as the company prepares for a transformative year.

Видео

No Data

There is no data to display

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Inc. (CING)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cingulate Inc. (CING)

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

US FDA declines to approve Cingulate's ADHD drug

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Why did Cingulate stock skyrocket today?

Видео

No Data

Пресс-релизы

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

US FDA declines to approve Cingulate's ADHD drug

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Why did Cingulate stock skyrocket today?

Видео

No Data

Пресс-релизы

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Search stocks

Cingulate Inc. (CING)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cingulate Inc. (CING)

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

US FDA declines to approve Cingulate's ADHD drug

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Why did Cingulate stock skyrocket today?

Видео

No Data

Пресс-релизы

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

US FDA declines to approve Cingulate's ADHD drug

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Why did Cingulate stock skyrocket today?

Видео

No Data

Пресс-релизы

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301